Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281514 · ClinicalTrials.gov registry record · Phase 1
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01281514 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 21 participants.
The verdict
NCT01281514, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboplatin and PLD together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with carboplatin and PLD in treating patients with relapsed ovarian epithelial, fallopian tube, or peritoneal cavity cancer
Interventions
- OTHER laboratory biomarker analysis
- DRUG carboplatin
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-12-14 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281514
The ClinicalTrials.gov registry entry for NCT01281514 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01281514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281514 about?
NCT01281514 is a clinical study titled "A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer". RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some o...
What is the current status of trial NCT01281514?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-12-14. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT01281514?
The interventions under investigation include: laboratory biomarker analysis (OTHER), carboplatin (DRUG), pegylated liposomal doxorubicin hydrochloride (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT01281514?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.